Seres Therapeutics, Inc.
MCRBHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Seres Therapeutics, Inc. focuses on Biotechnology services and products. Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company carries a $57.5M market cap, placing it firmly in the micro-cap category. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Market Cap
$57.5M
Beta
0.21
P/E (TTM)
—
P/E (Fwd)
-1.16
EPS (TTM)
$-2.42
EPS (Fwd)
$-4.95
ROE
-66.6%
ROA
-39.9%
Cash
$15.6M
Total Debt
$56.6M
Free CF
-$64.6M
52W Change
-69.3%
Annual Financials
Cash vs Debt
Where MCRB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MCRB finished 27.58% below its 150-day moving average ($7.65) and 43.98% below its 200-day moving average ($9.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MCRB overbought or oversold?
At the September 3, 2026 close, MCRB's RSI(14) was 70.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $15.6M in cash, though total debt stands at $56.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$64.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -66.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
MCRB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Seres Therapeutics, Inc.'s trajectory.